Abstract
Severe emergencies occurred across the globe, beginning with the outbreak of SARSCoV in 2002, followed by MERS-CoV in 2012. In December 2019, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China as the agent responsible for the recent COVID-19 pandemic outbreak. The virus rapidly spread throughout the world due to its high transmissibility, leading to enormous health problems and complexities. The COVID-19 pandemic has affected public health, the weak persons were severely affected by this virus. To stop the disease from spreading further, effective remedies are the need of the hour. Although SARS-CoV-2 vaccination campaigns are being carried out all over the globe, several new SARS-CoV-2 variants have emerged, and each has caused a wave of infections, highlighting an urgent need for therapeutics targeting SARS-CoV-2. Heterocyclic compounds have been explored extensively for a very long time for their biological activities, namely, anti-inflammatory, antimalarial, antitubercular, anticancer, antiviral, antimicrobial, antidiabetic, and many more bio-activities. Through this review, the author has tried to report the heterocyclic compounds synthesized all over the world over the last 2 years to fight against the SARS CoV-2 coronaviruses. The heterocyclic motifs mentioned in the review can serve as important resources for the development of COVID-19 treatment methods.
Keywords: Biological activities, COVID-19, drug, heterocyclic scaffolds, pandemic, SARS-CoV-2.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[http://dx.doi.org/10.1126/science.1085952] [PMID: 12730500]
[http://dx.doi.org/10.1056/NEJMoa1211721] [PMID: 23075143]
[http://dx.doi.org/10.1371/journal.pone.0249788] [PMID: 33822812]
[http://dx.doi.org/10.3389/fneur.2020.562634] [PMID: 33329305]
[http://dx.doi.org/10.1002/lary.29286] [PMID: 33219539]
[http://dx.doi.org/10.1177/0194599820981018] [PMID: 33320033]
[http://dx.doi.org/10.7326/M20-6976] [PMID: 33481642]
[http://dx.doi.org/10.1016/j.idc.2022.02.005] [PMID: 35636905];
b) Gavriatopoulou, M.; Korompoki, E.; Fotiou, D.; Ntanasis-Stathopoulos, I.; Psaltopoulou, T.; Kastritis, E.; Terpos, E.; Dimopoulos, M.A. Organ-specific manifestations of COVID-19 infection. Clin. Exp. Med., 2020, 20(4), 493-506.
[http://dx.doi.org/10.1007/s10238-020-00648-x] [PMID: 32720223]
[http://dx.doi.org/10.1016/j.dsx.2021.04.007] [PMID: 33892403];
b) Alkodaymi, M.S.; Omrani, O.A.; Fawzy, N.A.; Shaar, B.A.; Almamlouk, R.; Riaz, M.; Obeidat, M.; Obeidat, Y.; Gerberi, D.; Taha, R.M.; Kashour, Z.; Kashour, T.; Berbari, E.F.; Alkattan, K.; Tleyjeh, I.M. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin. Microbiol. Infect., 2022, 28(5), 657-666.
[http://dx.doi.org/10.1016/j.cmi.2022.01.014] [PMID: 35124265]
[http://dx.doi.org/10.1016/S0140-6736(20)30260-9] [PMID: 32014114]
[http://dx.doi.org/10.1016/j.fct.2021.112333] [PMID: 34118347]
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[http://dx.doi.org/10.1038/s41421-020-0153-3] [PMID: 32194980]
[http://dx.doi.org/10.3389/fphar.2021.704205] [PMID: 34867318]
[http://dx.doi.org/10.1038/s41586-020-2798-3] [PMID: 32967006]
[http://dx.doi.org/10.1016/S0140-6736(21)02758-6] [PMID: 34871545]
[http://dx.doi.org/10.1038/s41586-021-03402-9] [PMID: 33690265];
b) Nonaka, C.K.V.; Franco, M.M.; Gräf, T.; de Lorenzo Barcia, C.A.; de Ávila Mendonça, R.N.; de Sousa, K.A.F.; Neiva, L.M.C.; Fosenca, V.; Mendes, A.V.A.; de Aguiar, R.S.; Giovanetti, M.; de Freitas Souza, B.S. Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg. Infect. Dis., 2021, 27(5), 1522-1524.
[http://dx.doi.org/10.3201/eid2705.210191] [PMID: 33605869]
[http://dx.doi.org/10.1007/s43440-020-00155-6] [PMID: 32889701];
b) Rosa, S.G.V.; Santos, W.C. Clinical trials on drug repositioning for COVID-19 treatment. Rev. Panam. Salud Publica, 2020, 44, 1.
[http://dx.doi.org/10.26633/RPSP.2020.40] [PMID: 32256547]
[http://dx.doi.org/10.1038/s41467-020-18710-3] [PMID: 33028832]
[http://dx.doi.org/10.1007/s13181-020-00777-5] [PMID: 32356252]
[http://dx.doi.org/10.1016/j.genhosppsych.2021.02.006] [PMID: 33631694]
[http://dx.doi.org/10.1111/jce.14479] [PMID: 32270559];
b) Stevenson, A.; Kirresh, A.; Conway, S.; White, L.; Ahmad, M.; Little, C. Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified? Open Heart, 2020, 7(2), e001362.
[http://dx.doi.org/10.1136/openhrt-2020-001362] [PMID: 32817375]
[http://dx.doi.org/10.1038/s41598-021-97160-3] [PMID: 34497279]
[http://dx.doi.org/10.1021/cr300176g] [PMID: 23347156]
[http://dx.doi.org/10.2174/1385272823666191202105820]
[http://dx.doi.org/10.1021/jo051878h] [PMID: 16388628]
[http://dx.doi.org/10.1016/j.tet.2015.07.010]
[http://dx.doi.org/10.1007/s10593-021-02917-3] [PMID: 33994556]
[http://dx.doi.org/10.1039/D0RA09198G] [PMID: 35557843]
[http://dx.doi.org/10.1021/acs.jmedchem.0c01786];
b) U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 (December 22, 2021). [News release]. https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-firstoral-antiviral-treatmentcovid-19 (Accessed on: December 19, 2022).;
c) U.S. Food and Drug Administration (FDA). Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19. (December 23, 2021 11:08 am ET). [News release] https://www.merck.com/news/merck-andridgebacks-molnupiravir-receives-u-s-fda-emergency-useauthorization-for-the-treatment-of-high-risk-adults-with-mild-tomoderate-covid-19/(Accessed on: December 19, 2022).
[http://dx.doi.org/10.1002/ardp.201800225] [PMID: 30520524];
b) Wu, H.; Bock, S.; Snitko, M.; Berger, T.; Weidner, T.; Holloway, S.; Kanitz, M.; Diederich, W.E.; Steuber, H.; Walter, C.; Hofmann, D.; Weißbrich, B.; Spannaus, R.; Acosta, E.G.; Bartenschlager, R.; Engels, B.; Schirmeister, T.; Bodem, J. Novel dengue virus NS2B/NS3 protease inhibitors. Antimicrob. Agents Chemother., 2015, 59(2), 1100-1109.
[http://dx.doi.org/10.1128/AAC.03543-14] [PMID: 25487800]
[http://dx.doi.org/10.1016/j.bmc.2007.06.006] [PMID: 17587585]
[http://dx.doi.org/10.1016/j.ejmech.2012.11.040] [PMID: 23287058]
[http://dx.doi.org/10.1080/10426507.2016.1150277];
b) Kumar, V.; Sharma, S.; Husain, A. Synthesis and in vivo anti-inflammatory and analgesic activities of oxadiazoles clubbed with benzothiazole nucleus. Int. Curr. Pharm. J., 2015, 4(12), 457-461.
[http://dx.doi.org/10.3329/icpj.v4i12.25597]
[http://dx.doi.org/10.1002/ardp.201700304] [PMID: 29611883];
b) Tariq, S.; Kamboj, P.; Alam, O.; Amir, M. 1,2,4-Triazole-Based Benzothiazole/Benzoxazole Derivatives: Design, synthesis, p38α MAP kinase inhibition, anti-inflammatory activity and molecular docking studies. Bioorg. Chem., 2018, 81, 630-641.
[http://dx.doi.org/10.1016/j.bioorg.2018.09.015] [PMID: 30253336]
[http://dx.doi.org/10.1016/j.bmc.2015.05.019] [PMID: 26048024];
b) Hassan, A.Y.; Sarg, M.T.; Hussein, E.M. Design, synthesis, and anticancer activity of novel benzothiazole analogues. J. Heterocycl. Chem., 2019, 56(4), 1437-1457.
[http://dx.doi.org/10.1002/jhet.3524];
c) Narva, S.; Chitti, S.; Amaroju, S.; Goud, S.; Alvala, M.; Bhattacharjee, D.; Jain, N.; Kondapalli Venkata Gowri, C.S. Design, synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole analogues as antiproliferative agents. J. Heterocycl. Chem., 2019, 56(2), 520-532.
[http://dx.doi.org/10.1002/jhet.3427];
d) Yang, M.L.; Zhang, H.; Wang, W.W.; Wang, X.J. Design, synthesis, and evaluation of bis-benzothiazole derivatives as DNA minor groove binding agents. J. Heterocycl. Chem., 2018, 55(1), 360-365.
[http://dx.doi.org/10.1002/jhet.3041];
e) Hu, X.; Li, S.; He, Y.; Ai, P.; Wu, S.; Su, Y.; Li, X.; Cai, L.; Peng, X. Antitumor and antimetastatic activities of a novel benzothiazole-2-thiol derivative in a murine model of breast cancer. Oncotarget, 2017, 8(7), 11887-11895.
[http://dx.doi.org/10.18632/oncotarget.14431] [PMID: 28060755]
[http://dx.doi.org/10.3390/molecules22091490] [PMID: 28880242];
b) Demir Özkay, Ü.; Can, Ö.D. Sağlık, B.N.; Acar Çevik, U.; Levent, S.; Özkay, Y.; Ilgın, S.; Atlı, Ö. Design, synthesis, and AChE inhibitory activity of new benzothiazole–piperazines. Bioorg. Med. Chem. Lett., 2016, 26(22), 5387-5394.
[http://dx.doi.org/10.1016/j.bmcl.2016.10.041] [PMID: 27789142]
[http://dx.doi.org/10.3390/molecules26123526] [PMID: 34207756]
[http://dx.doi.org/10.1016/j.chemolab.2021.104421] [PMID: 34538993]
[http://dx.doi.org/10.1016/j.molstruc.2021.131782] [PMID: 34697505]
[http://dx.doi.org/10.1016/j.poly.2019.05.039];
b) Haribabu, J.; Jeyalakshmi, K.; Arun, Y.; Bhuvanesh, N.S.P.; Perumal, P.T.; Karvembu, R. Synthesis of Ni(II) complexes bearing indole-based thiosemicarbazone ligands for interaction with biomolecules and some biological applications. J. Biol. Inorg. Chem., 2017, 22(4), 461-480.
[http://dx.doi.org/10.1007/s00775-016-1424-1] [PMID: 27995332]
[http://dx.doi.org/10.1002/jhet.4257] [PMID: 34230687]
[http://dx.doi.org/10.1016/j.molstruc.2020.129829] [PMID: 33390613]
[http://dx.doi.org/10.1016/j.molstruc.2022.132747] [PMID: 35250091]
[http://dx.doi.org/10.1016/j.molstruc.2010.02.005]
[http://dx.doi.org/10.1016/j.bmcl.2010.09.021] [PMID: 20933408]
[http://dx.doi.org/10.1016/j.molstruc.2021.130961] [PMID: 34188314]
[http://dx.doi.org/10.1016/j.molstruc.2020.129230] [PMID: 32963413]
[http://dx.doi.org/10.3390/M371];
b) Kumar, V.S.; Mary, Y.S.; Pradhan, K.; Brahman, D.; Mary, Y.S.; Thomas, R.; Roxy, M.S.; Alsenoy, C.V. Synthesis, spectral properties, chemical descriptors and light harvesting studies of a new bioactive azo imidazole compound. J. Mol. Struct., 2020, 1199, 127035.
[http://dx.doi.org/10.1016/j.molstruc.2019.127035]
[http://dx.doi.org/10.1016/j.molstruc.2022.132869] [PMID: 35340531]
[http://dx.doi.org/10.1016/j.molstruc.2021.131246] [PMID: 34658419]
[http://dx.doi.org/10.1016/j.molstruc.2021.131263]
[http://dx.doi.org/10.1016/j.bioorg.2020.104497] [PMID: 33261847]
[http://dx.doi.org/10.1016/j.molstruc.2021.129981] [PMID: 33518802]
[http://dx.doi.org/10.1016/j.sjbs.2020.11.038] [PMID: 33199969]
[http://dx.doi.org/10.1016/j.molstruc.2020.129454] [PMID: 33100378]
[http://dx.doi.org/10.1002/slct.202001123] [PMID: 32518817]
[http://dx.doi.org/10.1016/j.molstruc.2020.129868] [PMID: 33424034]
[http://dx.doi.org/10.1016/j.arabjc.2021.103595] [PMID: 34909067]
[http://dx.doi.org/10.1126/science.abb3405] [PMID: 32198291]
[http://dx.doi.org/10.1126/science.abb4489] [PMID: 32321856]
[http://dx.doi.org/10.1021/acs.jmedchem.9b01828] [PMID: 32045235]
[http://dx.doi.org/10.1016/j.drudis.2020.06.017] [PMID: 32574699]
[http://dx.doi.org/10.1016/j.molstruc.2022.133659] [PMID: 35818577]
(b) U.S. Food and drug administration (FDA). Coronavirus (COVID-19) Update:FDA Authorizes First Oral Antiviral for Treatment of COVID-19.[News release] (Accessed on: December 19, 2022) https://www.fda.gov/drugs/emergencypreparedness-drugs/ coronavirus-covid-19-drugs;
(c) U.S. Food and drug administration (FDA).(2022, May 10) FDA Roundup: May 10, 2022. [Press release]. (Accessed on: December 19, 2022), https://www.fda.gov/newsevents/press-announcements/fda-roundup-may-10-2022